News summary produced by Claude AI
The Department of Health and Social Care announced plans to implement universal newborn screening for spinal muscular atrophy across England beginning in October 2027. The initiative will expand testing to include all babies born in the country, reaching an estimated 560,000 to 570,000 infants annually.
Spinal muscular atrophy is a rare genetic disorder affecting approximately one in 10,000 babies, with about 48 cases typically identified per year in the United Kingdom. The condition causes progressive muscle weakness, leaving affected individuals with limited mobility and potential respiratory and swallowing difficulties. Without early detection and intervention, the disease can be fatal within two years. However, infants diagnosed at birth can receive effective gene-therapy treatment that enables them to develop without experiencing the condition’s debilitating symptoms.
The announcement represents an expansion of a pilot program scheduled to begin in October, under which approximately 72% of English newborns were to receive screening. That limited rollout had drawn criticism for creating unequal access to testing across different regions. The universal screening program will utilize blood samples collected through heel-prick tests performed when infants are five days old. These samples will be analyzed at 13 laboratories across England, an increase from the current seven facilities. The screening will add SMA detection to existing tests for 10 other conditions, including cystic fibrosis, sickle cell disease, and chronic hypothyroidism.
Campaigners and patient advocacy groups welcomed the decision as a significant advancement. Public attention to the condition has increased partly due to advocacy efforts by public figures affected by SMA, who emphasized the importance of early detection for improved outcomes.